Royalty Pharma Statistics
Total Valuation
Royalty Pharma has a market cap or net worth of $12.31 billion. The enterprise value is $16.92 billion.
| Market Cap | 12.31B |
| Enterprise Value | 16.92B |
Important Dates
The last earnings date was Thursday, May 9, 2024, before market open.
| Earnings Date | May 9, 2024 |
| Ex-Dividend Date | May 16, 2024 |
Share Statistics
Royalty Pharma has 450.98 million shares outstanding. The number of shares has decreased by -1.61% in one year.
| Shares Outstanding | 450.98M |
| Shares Change (YoY) | -1.61% |
| Shares Change (QoQ) | +0.01% |
| Owned by Insiders (%) | 13.40% |
| Owned by Institutions (%) | 71.10% |
| Float | 388.12M |
Valuation Ratios
The trailing PE ratio is 15.41 and the forward PE ratio is 6.45. Royalty Pharma's PEG ratio is 1.18.
| PE Ratio | 15.41 |
| Forward PE | 6.45 |
| PS Ratio | 5.50 |
| Forward PS | n/a |
| PB Ratio | 1.25 |
| P/FCF Ratio | 4.70 |
| PEG Ratio | 1.18 |
Enterprise Valuation
The stock's EV/EBITDA ratio is 17.20, with an EV/FCF ratio of 6.46.
| EV / Earnings | 21.18 |
| EV / Sales | 7.56 |
| EV / EBITDA | 17.20 |
| EV / EBIT | 17.20 |
| EV / FCF | 6.46 |
Financial Position
The company has a current ratio of 12.52, with a Debt / Equity ratio of 0.62.
| Current Ratio | 12.52 |
| Quick Ratio | 12.48 |
| Debt / Equity | 0.62 |
| Debt / EBITDA | 6.24 |
| Debt / FCF | 2.34 |
| Interest Coverage | 5.33 |
Financial Efficiency
Return on equity (ROE) is 8.10% and return on invested capital (ROIC) is 5.87%.
| Return on Equity (ROE) | 8.10% |
| Return on Assets (ROA) | 4.90% |
| Return on Capital (ROIC) | 5.87% |
| Revenue Per Employee | $25.15M |
| Profits Per Employee | $8.98M |
| Employee Count | 89 |
| Asset Turnover | 0.14 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -17.24% in the last 52 weeks. The beta is 0.47, so Royalty Pharma's price volatility has been lower than the market average.
| Beta (1Y) | 0.47 |
| 52-Week Price Change | -17.24% |
| 50-Day Moving Average | 28.92 |
| 200-Day Moving Average | 28.57 |
| Relative Strength Index (RSI) | 36.31 |
| Average Volume (30 Days) | 2,758,291 |
Short Selling Information
The latest short interest is 13.75 million, so 3.05% of the outstanding shares have been sold short.
| Short Interest | 13.75M |
| Short Previous Month | 14.15M |
| Short % of Shares Out | 3.05% |
| Short % of Float | 3.54% |
| Short Ratio (days to cover) | 5.13 |
Income Statement
In the last 12 months, Royalty Pharma had revenue of $2.24 billion and earned $798.86 million in profits. Earnings per share was $1.77.
| Revenue | 2.24B |
| Gross Profit | 2.24B |
| Operating Income | 939.40M |
| Pretax Income | 798.86M |
| Net Income | 798.86M |
| EBITDA | 983.33M |
| EBIT | 983.33M |
| Earnings Per Share (EPS) | $1.77 |
Balance Sheet
The company has $1.53 billion in cash and $6.14 billion in debt, giving a net cash position of -$4.61 billion or -$10.22 per share.
| Cash & Cash Equivalents | 1.53B |
| Total Debt | 6.14B |
| Net Cash | -4.61B |
| Net Cash Per Share | -$10.22 |
| Equity / Book Value | 9.86B |
| Book Value Per Share | 21.87 |
| Working Capital | 1.44B |
Cash Flow
| Operating Cash Flow | 2.62B |
| Capital Expenditures | n/a |
| Free Cash Flow | 2.62B |
| FCF Per Share | $5.84 |
Margins
Gross margin is 100.00%, with operating and profit margins of 41.96% and 35.69%.
| Gross Margin | 100.00% |
| Operating Margin | 41.96% |
| Pretax Margin | 35.69% |
| Profit Margin | 35.69% |
| EBITDA Margin | 43.93% |
| EBIT Margin | 43.93% |
| FCF Margin | 116.98% |
Dividends & Yields
This stock pays an annual dividend of $0.84, which amounts to a dividend yield of 3.08%.
| Dividend Per Share | $0.84 |
| Dividend Yield | 3.08% |
| Dividend Growth (YoY) | 5.13% |
| Years of Dividend Growth | 4 |
| Payout Ratio | 47.46% |
| Buyback Yield | 1.61% |
| Shareholder Yield | 4.69% |
| Earnings Yield | 6.49% |
| FCF Yield | 21.27% |
Analyst Forecast
The average price target for Royalty Pharma is $46.75, which is 71.43% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $46.75 |
| Price Target Difference | 71.43% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 4 |
| Revenue Growth Forecast (5Y) | 6.21% |
| EPS Growth Forecast (5Y) | 22.06% |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
Royalty Pharma has an Altman Z-Score of 1.84 and a Piotroski F-Score of 6. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | 1.84 |
| Piotroski F-Score | 6 |